Could an HIV drug boost cervical cancer treatment?
NCT ID NCT03256916
First seen Jan 04, 2026 · Last updated May 06, 2026 · Updated 21 times
Summary
This study tested whether adding the HIV drug nelfinavir to standard chemoradiation helps people with advanced cervical cancer live longer without the disease coming back. About 348 adults with stage III cervical cancer took part. One group got standard treatment, and the other got nelfinavir before and during standard treatment. The goal was to see if the drug improves 3-year disease-free survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA CERVIX,STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tata Memorial Centre
Mumbai, Maharashtra, 400012, India
Conditions
Explore the condition pages connected to this study.